Ann: NTCELL demonstrates continued reversal of Parkinsons-LCT.AX, page-60

If you look back at prior annoucements management are actually quite conservative in their wording. The last trial update released in January showed exactly the same results as yesterday's update which generated little market interest.

The company has recently secured funding to complete the current trial so I don't beleive yesterdays announcement was simply to raise more money.

As the initial trial involved only 4 patients, although the results are extremely promising, there is still a lot that can go wrong along the road the commercialisation.

I beleive long term holders will be rewarded but as the price movement has shown following any announcement over the past few years those looking to make a quick buck are quickly dissapointed.